Join our April 5 webinar where Ping Huang, Director, Head of DS BioProcesses, OED, Abbvie at Redwood and Masayoshi Nagaya, Sr. Global Technology Manager at JSR Life Sciences will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie.
Tokyo – Nov. 21, 2017 – JSR Corporation announced today that it held the opening ceremony of the JSR-Keio University Medical and Chemical Innovation Center (JKiC) on October 28 at the Keio University Shinanomachi Campus.
On Wednesday September 13th, our colleague Gerald Platteau gave a presentation about the purification of antibody fragments with Amsphere™ A3 protein A resin.
He talked about:
· Antibody fragment types that can be purified with protein A resin
· Amsphere A3 binding sites in VHH single domain antibodies and VH domains
· Dynamic binding capacity data of Amsphere A3 for different antibody (fragment) formats
· Advantages of a Protein A resin for antibody fragment capture, compared to other resin types
JSR Corporation (JSR) announced that it has agreed to acquire Lexi Co., Ltd. (Lexi) a medical 3D software company. Through this acquisition, JSR will establish a new business in life sciences by integrating Lexi's 3D software technology with JSR's 3D printing and materials technologies. The JSR Group is focused on creating novel value and capitalizing on the trend toward digitization in the medical and life sciences industries.
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies
Tokyo, Japan - May 9, 2017 – JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of Amsphere™ A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase its production capacity by 6 times and provide all-important redundancy in its manufacturing capability.
For several years, the JSR Life Sciences team worked closely with the LFB team at the bioproduction facility in Alès (LFB Biomanufacturing), cumulating in the implementation of the Amsphere™ A3 Protein-A media in clinical Phase II manufacturing of a monoclonal antibody. LFB recently tripled the production capacity of this facility, which also provides biomanufacturing services. The Amsphere™ A3 media offered LFB Biomanufacturing the best productivity, excellent impurity clearance and outstanding process economics in manufacturing scale.
In a joint effort, Oncobiologics INC and JSR Life Sciences released a poster on the optimization of a Protein A Chromatography Process for a Herceptin® Biosimilar (Trastuzumab). Four Protein A resins from leading industry vendors, including AmsphereTM A3, were screened for use in the capture step for a Trastuzumab and multiple parameters were assessed for their performance against the platform resin.
JSR Life Sciences has signed a technology licensing and joint development agreement for the Chromassette® technology with SPF Technologies, LLC, a private Somerville, MA‐based company providing innovative solutions for biopharmaceutical manufacturing.